Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3479460 | 1.00 | BACE1 (0.40) | BACE1PTGS2PTGS1SIGMAR1 | |
| SCHEMBL2819803 | 0.86 | PTGS2 (0.38) | BACE1PTGS2PTGS1SIGMAR1 | |
| SCHEMBL2820113 | 0.83 | PTGS2 (0.36) | BACE1PTGS2PTGS1SIGMAR1 | |
| SCHEMBL3479542 | 0.82 | BACE1 (0.45) | BACE1SIGMAR1 | |
| SCHEMBL13031031 | 0.82 | BACE1 (0.45) | BACE1SIGMAR1 | |
| SCHEMBL2818277 | 0.80 | PTGS2 (0.35) | BACE1PTGS2PTGS1SIGMAR1 | |
| SCHEMBL3479560 | 0.78 | MCHR1 (0.43) | BACE1SIGMAR1 | |
| SCHEMBL8179365 | 0.77 | PTGS2 (0.41) | BACE1PTGS2PTGS1SIGMAR1 | |
| SCHEMBL3479445 | 0.77 | BACE1 (0.58) | BACE1 | |
| SCHEMBL3479511 | 0.77 | BACE1 (0.58) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | claimed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2063889-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008030412-A2 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | BACE1 1/4885PTGS2 1739/4885PTGS1 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.